Scott N. Holden

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 596 citations

Medicine, Oncology, Pharmacology +17

Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer

Adrian M. Jubb, Herbert I. Hurwitz, Wei Bai et al. · Journal of Clinical Oncology · 2005 · 389 citations · Full text

Medicine, Oncology, Pharmacology +17

Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

William L. Ince, Adrian M. Jubb, Scott N. Holden et al. · JNCI Journal of the National Cancer Institute · 2005 · 322 citations

Medicine, Oncology, Pharmacology +17

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

Scott N. Holden, Sabine Eckhardt, R. Basser et al. · Annals of Oncology · 2005 · 306 citations · Full text

Medicine, Oncology, Pharmacology +15

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Sandhya Girish, Manish Gupta, Bei Wang et al. · Cancer Chemotherapy and Pharmacology · 2012 · 265 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17